Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 12.92% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | -326.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -326.86% |
| Mar 31, 2026 | -246.79% |
| Dec 31, 2025 | 27.36% |
| Sep 30, 2025 | -14.52% |
| Jun 30, 2025 | 145.34% |
| Mar 31, 2025 | 76.74% |
| Dec 31, 2024 | -29.69% |
| Sep 30, 2024 | 69.89% |
| Jun 30, 2024 | 30.21% |
| Mar 31, 2024 | 13.21% |
| Dec 31, 2023 | -661.61% |
| Sep 30, 2023 | 24.65% |
| Jun 30, 2023 | 43.44% |
| Mar 31, 2023 | 18.30% |
| Dec 31, 2022 | 91.77% |
| Sep 30, 2022 | -90.45% |
| Jun 30, 2022 | -132.58% |
| Mar 31, 2022 | -115.13% |
| Dec 31, 2021 | -1,273.27% |
| Sep 30, 2021 | -662.90% |